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Introduction 
Bernhard Schwartländer, Barbara Bek, Horst Skarabis*, 
Judith Koch, Jörg Burkowitz* and Meinrad A. Koch 
for the multicentre cohort study group t 
Objective: To evaluate whether the use of immunological markers in addition to CD4+ 
Iymphocyte count can improve the prediction of the probability of developing AIDS 
within a given period. 
Design and setting: Prospective multicentre cohort study of homosexual men. 
Patients: A total of 447 HIV-positive homosexual men followed prospectively at 6-month 
intervals (median time of observation, 47 months). 
Methods: Estimation of AIDS-free time using lifetable plots by Cutler and Ederer and 
Weibull parametric models. A stepwise multivariate regression analysis was used to 
calculate the optimal combination of the parameters studied. 
Results: In general CD4+ Iymphocyte counts are most important for the prediction of 
AIDS-free time. The use of serum levels of ß2-microglobulin (ß2M), immunoglobulin A 
(lgA) and erythrocyte sedimentation rate (ESR) can significantly improve the predictive 
value of CD4 + Iymphocyte counts. However, the usefulness of these parameters 
depends on the stage of HIV disease. In patients with a CD4 + Iymphocyte count 
> 500 x 106/1, only IgA level had a significant predictive value; none of the other 
parameters significantly improved the model. In patients with a CD4 + Iymphocyte 
count< 500 x 106/1, the absolute number of CD4+ cells itself was the most important 
single predictive parameter, but the prediction of AIDS was significantly improved by 
the addition of the other parameters investigated. The most powerful combination of 
parameters in this group was CD4 + count, ß2M and ESR. 
Conclusion: Determination of serum IgA, ß2M and ESR in addition to CD4 + 
Iymphocyte count may aid the choice of specific therapeutic regimens or systems of 
care for HIV-positive individuals. 
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CD4 lymphocyte count is the best prognostic indicator 
of the course of HN disease and is routinely used to 
decide when to initiate antiretroviral treatment with zi-
dovudine or Pneumocystis carinii pneumonia (PCP) 
prophylaxis with pentamidine [1-4]. However, its reli-
ability is limited because of considerable variability due 
to laboratory [5], biological [6] and individual [7,8] 
factors. In addition, the progression of HN disease 
in individuals who at one point had the same Co4 + 
lymphocyte count may differ substantially. Because of 
these limitations many studies have investigated other 
or additional potential prognostic parameters, includ-
ing presence of free p24 antigen in serum [9-11], 
loss of anti-p24 antibodies [5,12], serum neopterin 
[13-16], serum ß2-rnicroglobulin (ß2M) [10,12,17-20] 
and serum interferon [21] levels. p24 antigen and anti-
p24 antibodies are HN-specific markers; neopterin 
and ß2M levels may be elevated because of other infec-
From the AIDS Centre, Federal Health Office and *Free University, Berlin, Germany. tSee Appendix. 
Requests for reprints to: Dr Bernhard Schwartländer, AIDS-Zentrum im BGA, Reichpietschufer 74-76, D-1000 Berlin 30, Germany. 
Date of receipt: 9 December 1992; revised: 26 February 1993; accepted: 5 March 1993. 
© Current Science Ud ISSN 0269-9370 813 
814 AIDS 1993, Vol 7 No 6 
tions or autoimmune and neoplastic diseases [22,23]. 
Progression to AIDS is also reported to be assoeiated 
with increased levels of immunoglobulin (Ig) G [24] 
and IgA [17,19,24] and an increased erythrocyte sedi-
mentation rate (ESR) [17]. 
None of these additional parameters has the predictive 
potential of CD4 + lymphocyte count; their predictive 
value in combination with CD4 + lymphocyte count is 
confroversial [13,14,17,20,21,25-27]. 
To evaluate whether the prediction of AIDS can 
be improved by combining different immunological 
markers, we analysed the predictive value of CD4 + 
lymphocyte count, ß2M, immunoglobulins and ESR 
alone and in combination using data from the Ger-
man multicentre AIDS cohort study. 
Patients and methods 
Study population 
Data on 447 HN-positive homosexual men from the 
prospective multicentre cohort study of the Federal 
Health Office, Germany (which started in October 
1984) were analysed. Individuals with other risk be-
haviours for HN infection, such as intravenous drug 
use, were exc1uded from the study during recruitment. 
The mean age at enrolment was 34 years (range, 18--65 
years). Cohort members are examined at 6-month in-
tervals. Each visit inc1udes medical his tory, physical ex-
amination, and serological and immunological testing. 
At enrolment 49% of the subjects were asymptomatic, 
31% had minor symptoms such as lymphadenopathy, 
and 20% had AIDS-related conditions. The median 
observation period was 47 months (5th and 95th 
percentiles, 6 and 84 months). During the period of 
observation 163 (36.5%) individuals developed AIDS. 
Opportunistic infections were the most frequent AIDS 
manifestations (71.3%), followed by Kaposi's sarcoma 
(15.3%) and lymphoma (4.9%). 
During the period of investigation 37 subjects received 
zidovudine before developing AIDS, of whom 31 re-
ceived it for less than 12 months. Twenty-four subjects 
received primary prophylaxis for PCP, four for more 
than 12 months. 
Laboratory testing 
CD4+ lymphocyte counts (flow cytometry) and ESR 
determinations (in mm after 1 h) were performed at 
the study centres. ß2M titres (radioimmunoassay; Phar-
maeia, Freiburg, Germany) and Ig levels were deter-
mined at the central laboratory. 
Statistical methods 
Survival analyses were performed to determine the 
predictive value of the various parameters, both alone 
and in combination. The end-point was the onset of 
AIDS; the starting-points were the times when a spe-
eific threshold of a certain parameter was first ob-
served in an individual. Lifetable plots by Cutler and 
Ederer were used to show the distribution of AIDS-
free time for groups with different starting-points. 
Since non-parametric product-limit estimators can 
be biased for heavily censored data, we used a 
Weibull parametric model for further analysis. Appli-
cability of Weibull family was checked by plotting 
10g(Iog( -F(t») as a function oflog(t). We determined 
whether observed differences were statistically signifi-
cant by comparing the 95% confidence intervals (cI) 
of the median AIDS-free time. To determine the rela-
tive importance of the different covariates, a stepwise 
regression model was calculated using the statistical 
software package UMDEP 6.0 [28]. 
Results 
We first investigated the extent to which defined 
starting-points were associated with remaining AIDS-
free time (Figs la--e). AIDS-free time was strongly 
correlated with CD4 + lymphocyte count. IgG, IgA, 
ß2M and ESR also had a predictive value (Fig. 1). 
However, each of these parameters was less power-
ful in predicting AIDS-free time than CD4 + count. 
IgM level had no predictive value and was therefore 
exc1uded from further analysis. 
To analyse whether the predictive power of the differ-
ent parameters investigated depends on stage of HN 
disease, as reflected by the number of CD4 + lympho-
cytes, subject data were assigned to groups with differ-
ent starting-points for CD4 + count ( < 200, 200--500 
and > 500 x 106/1). 
For each of these CD4 + lymphocyte count groups, 
we analysed whether introduction of a second para-
meter improved the predictive power. For this pur-
pose threshold levels of the other parameters were 
defined on the basis of the observed results (Figs 
1a--e) and clinical or immunological experience (IgG 
> 16.0 g/l, IgA > 3.5 g/l, ß2M > 3.5 mg/I, and ESR 
> 9 mm after 1 h). We then calculated AIDS-free time 
for the three CD4 + count groups after stratification 
according to the thresholds of the additional parame-
ters. 
The results are shown in Tables 1--4 and Figs 2-5. 
ß2M level had an additional predictive value in all 
CD4 + count groups (Figs 2a--c). In all groups the 
median AIDS-free time was at least twice as long in 
subjects with a ß2M level ::::; 3.5 mg/I compared with 
subjects with a ß2M level> 3.5 mg/I. However, this dif-
ference was only statistically significant for the group 
with CD4 + counts between 200 and 500 x 106/1. 
For IgA, there were substantial differences in AIDS-free 
time between the groups with CD4 + counts < 200 
and > 500 x 106/1 (Figs 4a--c). ESR had an addi-
tional predictive value only in the two groups with 
CD4 + counts < 500 x 106/1 (Figs 3a--c). The addi-
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Fig. 1. Survival plots stratified for (a) CD4 Iymphocyte count; (b) serum ß2-microglobulin; (cl serum immunoglobulin (lg) A; (d) serum IgG; 
(e) erythrocyte sedimentation rate. The end-point for survival analysis was the onset of AIDS; the starting-point was the time when the 
respective parameter reached a given threshold for the first time in an individual. 
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Fig. 2. AIDS-free time (Weibull model) for patients with a CD4 + 
Iymphocyte count> 500 (a), 200--500 (b) and < 200 (c) x 106/1 
stratified for given levels of ß2-microglobulin (ß2M; mg/I) at base-
line. 
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Fig. 3. AIDS-free time (Weibull model) for patients with a CD4 + 
Iymphocyte count> 500 (a), 200--500 (b) and < 200 (c) x 106/1 
stratified for given erythrocyte sedimentation rate (ESR) values 
(mm after 1 h) at baseline. 
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Fig. 4. AIDS-free time (Weibull modell for patients with a CD4 + 
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stratified for given levels of serum immunoglobulin A OgA; g/D at 
baseline. 
tional predictive value of IgG was low in all CD4 + 
count groups (Figs 5a-c); it was therefore excluded 
from further analysis. 
This first analysis showed that the predictive value of 
additional parameters varied depending on CD4 + 
count group. To assess the optimal combination of 
parameters for each of the three CD4 + count groups, 
we calculated the probability of developing AIDS us-
ing a stepwise regression model with CD4 + count, 
IgA, ß2M and ESR as independent variables. We evalu-
ated all combinations in order to control for interactive 
effects between the different parameters. 
The results of this analysis are shown in Figs 6a-c. 
The most powerful predictor for each of the CD4 + 
count groups was introduced as the first parameter 
and is shown at the top of the tree. Significant im-
provement (p::;; 0.05) of the model (by addition of 
a given covariate) is illustrated by solid lines. Dotted 
lines illustrate combinations that did not significantly 
improve (p> 0.05) the model. 
The combination of parameters giving the best pre-
diction of developing AIDS differed in all three 
CD4 + count groups. Only IgA level had a signifi-
cant predictive value in the group with CD4 + counts 
> 500 x 106/1. None of the other parameters signif-
icantly improved the model (Fig. 6a). In the two 
groups with CD4 + counts < 500 x 106/1, the abso-
lute number of CD4 + cells itself was the most im-
portant single predictive parameter (i.e., to predict 
the probability that a patient with a CD4 lympho-
cyte count < 200 x 106/1 will develop AIDS within 
a given period, it is of greatest significance to know 
whether that patient' s CD4 + count is, for example, 
20 or 190 x 106/0. 
For patients with CD4 + counts between 200 and 
500 x 106/1, the combination of CD4 + count, ß2M 
and ESR best predicted progression to AIDS (Fig. 6b). 
The addition of ß2M or ESR to any combination of the 
other covariates improved the model significantly. 
In the group with CD4 + counts < 200 x 106/1, the 
addition of any of the other covariates to CD4 + 
count improved the prediction of AIDS significantly 
(Fig. 6c). As for subjects with CD4 + counts between 
200 and 500 x 106/1, the most powerful combination 
was CD4 + count, ß2M and ESR. This combination was 
not improved by the addition of IgA . 
Discussion 
Our objective was to determine whether the predictive 
value of CD4 + lymphocyte count can be improved 
by the use of additional prognostic markers. Our data 
show that ß2M, IgA and ESR supply such additional 
information. 
An important result of this study is that the usefulness 
of the parameters analysed depends on the stage of 
HN disease as indicated by CD4 + lymphocyte count. 
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Fig. 6. Evaluat ion of the predict ive value of different combina-
tions of CD4 + Iymphocyte count, ß2-microglobulin (ß2M), im-
munoglobulin AlIgA) and erythrocyte sedimentation rate (ESR) 
using a mu ltivariate stepwise analysis. The most powerful predic-
tor for each of the CD4 + count groups is shown at the top of 
the tree. A significant improvement (P :::; 0.05) of the model by 
adding a given covariate is illustrated by solid lines. P values are 
shown next to the lines. 
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Table 1. Distribution 01 AIDS-Iree time (Weibull distribution) strati lied by 
CD4 + Iymphocyte count and ßTmicroglobulin (ß2M). 
AIDS-Iree time (months) 
CD4+ count ß2M 25% Median 75% 
(x 106/1) (mg/I) No. percentile (95% CI) percentile 
>500 269 146 81 (64-98) 38 
:$ 3.5 235 146 85(67-103) 43 
> 3.5 34 106 48(15-81) 17 
200-500 258 93 56(47-65) 30 
:$3.5 193 114 67 (51-82) 34 
>3.5 65 57 38 (31-45) 24 
<200 109 66 14(6-22) 2 
:$3.5 45 154 47(6-87) 10 
>3.5 64 27 6(2-10) 
CI, confidence interval. 
Table 2. Distribution of AIDS-free time (Weibull distribution) stratified by 
CD4+ Iymphocyte count and serum immunoglobulin A (lgA). 
AIDS-free time (months) 
CD4+ count IgA 25% Median 75% 
(x 106/1) (gll) No. percentile (95% CI) percentile 
>500 269 146 81 (64-98) 38 
:$3.5 212 156 92(71-113) 47 
>3.5 57 84 43 (26-61) 19 
200-500 258 93 56 (47-65) 30 
:$3.5 183 93 59(49-70) 33 
>3.5 75 86 48 (31-64) 23 
<200 109 66 14 (6-22) 2 
:$3.5 34 139 45 (3-86) 11 
>3.5 75 37 8(2-13) 1 
CI, confidence interval. 
Table 3. Distribution 01 AIDS-free time (Weibull distribution) stratified by 
CD4+ Iymphocyte count and serum immunoglobulin G (lgG). 
CD4+ count 
(x 106/ 1) 
>500 
200-500 
<200 
IgG 
(gI1) 
:$16.0 
>16.0 
:$16.0 
>16.0 
:$16.0 
> 16.0 
CI, confidence interval. 
AIDS-free time (months) 
25% Median 75% 
No. percentile (95% CI) percentile 
269 146 81 (64-98) 38 
132 140 87(66-109) 48 
137 140 71 (48-94) 30 
258 93 56(47-65) 30 
88 92 64(48-81) 41 
170 88 51 (40-62) 26 
109 66 14(6-22) 2 
25 233 19(0-58) 1 
84 47 13(6-20) 3 
This finding is in agreement with the results of arecent 
study of a cohort of homosexual men with known date 
of seroconversion [21] , which analysed the predictive 
power of different immune markers at specmed times 
after HN infection. Because the date of seroconver-
Table 4. Distribution 01 AIDS-free time (Weibu ll distribution) stratified by 
CD4 + Iymphocyte count and erythrocyte sedimentation rate (ESR). 
AIDS-Iree time (months) 
ESR 25% CD4+ count 
(x 106/1) (mm alter 1 h) No. percentile 
>500 420 145 
:$9 303 122 
> 9 117 183 
200-500 402 93 
:$9 249 94 
>9 153 83 
<200 170 60 
:$9 50 183 
> 9 120 34 
CI, conlidence interval. 
Median 
(95% CI) 
85 (72-98) 
82 (71-94) 
80(47- 114) 
57(50-65) 
63(54-73) 
47(37-57) 
13 (7- 19) 
49(3-95) 
8(4-12) 
75% 
percentile 
43 
50 
28 
31 
39 
23 
2 
9 
sion for HN-positive individuals is rarely known in a 
clinical setting, it is difficult to apply these results to 
most of the patients in clinical care. 
We stratified subjects according to the time when their 
CD4+ lymphocyte count first fell below a speci-
fied threshold. Since measurement of CD4 + count 
of HN-positive individuals in clinical care is routine, 
the results of our study are applicable to the majority 
of patients. Controversial results from previous studies 
on the predictive value of the parameters analysed may 
in part be explained by lack of stratification according 
to the stage of HN disease. 
The most important parameter for the prediction of 
AIDS was absolute number of CD4 + cells for sub-
jects with a CD4 + lymphocyte count< 500 x 106/ 1, 
whereas only serum 19A level correlated with AIDS-free 
time in subjects with a CD4 + count> 500 x 106/1. 
In patients with CD4 + counts < 500 x 106/ 1 the ad-
ditional parameters improved the predictive power of 
the absolute number of CD4 + cells significantly. The 
best combination was CD4 + count, ß2M and ESR. 
There is no clear explanation why serum 19A level 
had a predictive value in patients with higher CD4 + 
counts. It may reflect non-specific stimulation of the 
humoral immune system, rather than being a conse-
quence of early mucosal infections. Increased levels 
of ß2M are associated with cell destruction, signalling 
the multiplication of the virus or other cytocidal events, 
such as auto immune phenomena or inflammatory pro-
cesses. Increased ESR may simply indicate advanced 
immune deficiency and the ensuing increasingly se-
vere opportunistic infections. Infections such as oral 
candidiasis have been shown to predict progression 
to AIDS [29] . In our study analyses using such 'minor' 
opportunistic infections as indicators of AIDS-free time 
did not show significant results. A possible reason for 
this could be the difficulty in quantifying the severity of 
these infections and/or confounders such as self-medi-
cation (not uncommon in the homo sexual community 
in Germany). 
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Antiretroviral therapyand prophylaxis should be taken 
into account when estimating AIDS-free time. Our re-
sults were not altered by exclusion of the small num-
ber of subjects who had received zidovudine and/ or 
pentamidine prophylaxis. Because of their small num-
ber, comparison of patients who had received anti-
retroviral therapy and/ or prophylaxis vvith patients 
who had not was not meaningful. However, several 
studies have shown that zidovudine and pentamidine 
prolong AIDS-free time [30-32]; groups of subjects 
where the majority have received zidovudine or pri-
mary prophylaxis of opportunistic infections may take 
a significantly longer time to develop AIDS. Median 
AIDS-free times and the prognostic values of the im-
munological markers calculated in our study should be 
considered baseline values for untreated patients. 
Recent studies have shown that elevated ß2M levels 
decline on zidovudine treatment [33-36] . Further in-
vestigations are necessary to determine whether such 
parameters are useful predictors of AIDS-free time in 
patients receiving treatment. 
The determination of serum 19A, ß2M and ESR in ad-
dition to CD4 + lymphocyte count may aid the choice 
of specific therapeutic regimens or systems of care -
for example, when Gf at all) a subject should begin to 
take zidovudine or other antiretroviral compounds. 
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Appendix 
The multicentre cohort study group of the Federal 
Health Office, Germany comprises: B. Friedrich-
]änicke, Landesinstitut für Tropenmedizin, Berlin; 
E.B. Helm, Zentrum Innere Medizin der Universität, 
Frankfurt/Main; S. Schwander, Bernhard Nocht In-
stitut, Hamburg; R. Gerdelmann, Staatl. Medizinalun-
tersuchungsamt, Hannover; H. Rasokat, Universität 
Hautklinik, Köln; E. Thoma, Dermatologische Klinik 
der Universität, München; J. Bogner, Med. Poliklinik 
der Universität, München; F.E. Krapf, Immunologis-
ches Institut der Universität, Erlangen, Germany. 
